Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Nat Prod ; 71(2): 186-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18217716

ABSTRACT

Brominated indole alkaloids are a common class of metabolites reported from sponges of the order Verongida. Herein we report the isolation, structure determination, and activity of metabolites from three Florida sponges, namely, Verongula rigida (order Verongida, family Aplysinidae), Smenospongia aurea, and S. cerebriformis (order Dictyoceratida, family Thorectidae). All three species were investigated chemically, revealing similarities in secondary metabolites. Brominated compounds, as well as sesquiterpene quinones and hydroquinones, were identified from both V. rigida and S. aurea despite their apparent taxonomic differences at the ordinal level. Similar metabolites found in these distinct sponge species of two different genera provide evidence for a microbial origin of the metabolites. Isolated compounds were evaluated in the Porsolt forced swim test (FST) and the chick anxiety-depression continuum model. Among the isolated compounds, 5,6-dibromo- N,N-dimethyltryptamine ( 1) exhibited significant antidepressant-like action in the rodent FST model, while 5-bromo- N,N-dimethyltryptamine ( 2) caused significant reduction of locomotor activity indicative of a potential sedative action. The current study provides ample evidence that marine natural products with the diversity of brominated marine alkaloids will provide potential leads for antidepressant and anxiolytic drugs.


Subject(s)
Antidepressive Agents/isolation & purification , Antidepressive Agents/pharmacology , Hydrocarbons, Brominated/isolation & purification , Hydrocarbons, Brominated/pharmacology , Indole Alkaloids/isolation & purification , Indole Alkaloids/pharmacology , N,N-Dimethyltryptamine/analogs & derivatives , N,N-Dimethyltryptamine/isolation & purification , N,N-Dimethyltryptamine/pharmacology , Porifera/chemistry , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/isolation & purification , Anti-Anxiety Agents/pharmacology , Antidepressive Agents/chemistry , Chickens , Disease Models, Animal , Dose-Response Relationship, Drug , Florida , Hydrocarbons, Brominated/chemistry , Indole Alkaloids/chemistry , Marine Biology , Mice , Molecular Structure , N,N-Dimethyltryptamine/chemistry
2.
Pharmacol Biochem Behav ; 89(1): 46-53, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18037479

ABSTRACT

The marine environment is a valuable resource for drug discovery due to its diversity of life and associated secondary metabolites. However, there is very little published data on the potential application of marine natural products to treat neuropsychiatric disorders. Many natural products derived from chemically defended organisms in the marine environment have pharmacophores related to serotonin or clinically utilized antidepressant drugs. Therefore, in the present study, compounds selected for their structural similarity to serotonin or established antidepressants were evaluated for antidepressant-like activity using the forced swim and tail suspension tests in mice. The antidepressant positive controls, citalopram (selective serotonin reuptake inhibitor) and despiramine (tricyclic antidepressant) both dose-dependently reduced immobility time in the forced swim and tail suspension tests. Two marine natural product compounds tested, aaptamine and 5,6-dibromo-N,N-dimethyltryptamine, also produced significant antidepressant-like activity in the forced swim test. In the tail suspension test, the antidepressant-like effects of 5,6-dibromo-N,N-dimethyltryptamine were confirmed, whereas aaptamine failed to produce significant results. None of the tested compounds induced hyperlocomotion, indicating that nonspecific stimulant effects could not account for the observed antidepressant-like actions of the compounds. These studies highlight the potential to rationally select marine derived compounds for treating depression and other neuropsychiatric disorders.


Subject(s)
Antidepressive Agents/pharmacology , Biological Products/pharmacology , Animals , Antidepressive Agents/chemistry , Antidepressive Agents, Tricyclic/pharmacology , Biological Products/chemistry , Citalopram/pharmacology , Desipramine/pharmacology , Drug Evaluation, Preclinical , Hindlimb Suspension/psychology , Male , Mice , Mice, Inbred DBA , Motor Activity/drug effects , Swimming/psychology
3.
Expert Opin Drug Discov ; 2(11): 1505-22, 2007 Nov.
Article in English | MEDLINE | ID: mdl-23484601

ABSTRACT

With ∼ 40 years of research completed after the development of self-contained underwater breathing apparatus, drug discovery opportunities in the sea are still too numerous to count. Since the FDA approval of the direct-from-the-sea calcium channel blocker ziconotide, marine natural products have been validated as a source for new medicines. However, the demand for natural products is extremely high due to the development of high-throughput assays and this bottleneck has created the need for an intense focus on increasing the rate of isolating and elucidating the structures of new bioactive secondary metabolites. In addition to highlighting the drug discovery potential of the marine environment, this review discusses several of the pressing needs to increase the rate of drug discovery in marine natural products, and describes some of the work and new technologies that are contributing in this regard.

SELECTION OF CITATIONS
SEARCH DETAIL
...